Bioavailability, multiple-dose pharmacokinetics, and biotransformation of the aldose reductase inhibitor zopolrestat in dogs

Drug Metabolism and Disposition

Volumn 26, Issue 11, 1998, Pages 1160-1166

  Schneider, Richard P ^b   Davenport, Cynthia J ^b   Hoffmaster, Keith A ^b   Inskeep, Philip B ^a  

^a PFIZER INC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; CARBON 14; ZOPOLRESTAT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONJUGATION; DRUG ELIMINATION; DRUG FECES LEVEL; DRUG TRANSFORMATION; DRUG URINE LEVEL; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ALDEHYDE REDUCTASE; ANIMALS; BENZOTHIAZOLES; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; DOGS; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; HALF-LIFE; HYPOGLYCEMIC AGENTS; MALE; MASS SPECTROMETRY; PHTHALAZINES; THIAZOLES;

ANIMALIA; CANIS FAMILIARIS;

EID: 0031738506     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Beyer TA, Siegel TW, Beebe DA, Aldinger CE, Ellery CA, Ashton MA, Pustilnik LR and Morehouse LA (1990) Low doses of aldose reductase inhibitors dissociate sorbitol accumulation from myo-inositol depletion in tissues of the diabetic rat. Diabetes 39(Suppl 1):187A.
2. Inskeep PB, Chin EB, Henry EW, Lazar JD, Conrad K, Reed AE and Ronfeld RA (1996) The effect of urinary pH and now rate on the renal elimination of zopolrestat and zopolrestat glucuronide in humans. Am J Ther 3:219-224.
3. Inskeep PB, Reed AE, Connolly AG, Wilner KD, Vargas R and McMahon FG (1995) Pharmacokinetics in non-insulin dependent diabetics of the aldose reductase inhibitor, zopolrestat. Am J Ther 2:112-118.
4. Inskeep PB, Reed AE and Ronfeld RA (1991) Pharmacokinetics of zopolrestat, a carboxylic acid aldose reductase inhibitor, in normal and diabetic rat. Pharm Res 8:1511-1515.
5. Inskeep PB, Ronfeld RA, Peterson MJ and Gerber N (1994) Pharmacokinetics in man of the aldose reductase inhibitor, zopolrestat. J Clin Pharmacol 34:760-766.
6. Kinoshita JH and Nishimura C (1988) The involvement of aldose reductase in diabetic complications. Diabetes Metab Rev 4:323-337.
7. Mylari BL, Larson ER, Beyer TA, Zembrowski W, Aldinger C, Dee M, Siegel T and Singleton D (1991) Novel, potent aldose reductase inhibitors: 3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2 benzothiazolyl]methyl]-1-phthalazineacetic acid (zopolrestat) and congeners. J Med Chem 34:108-122.
8. Oates PJ and Ellery CA (1990) Aldose reductase inhibitors sorbinil and CP-73,850 prevent galactose-induced hyperperfusion of the renal cortex. Diabetes 39(Suppl 1):184A.
9. Raskin P and Rosenstock J (1987) Aldose reductase inhibitors and diabetic complications. Am J Med 83:298-306.
10. Schneider RP, Fouda HG and Inskeep PB (1998) Tissue distribution and biotransformation of zopolrestat, an aldose reductase inhibitor, in rats. Drug Metab Dispos 26:1149-1159.